A single-institution experience of performing bloodless transplant in Jehovah's Witness patients | Zendy

Alexander Coltoff | Zendy; Aditya Shreenivas | Zendy; Solmaz Afshar | Zendy; Amir Steinberg | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

A single-institution experience of performing bloodless transplant in Jehovah's Witness patients

Author(s) -

Alexander Coltoff,

Aditya Shreenivas,

Solmaz Afshar,

Amir Steinberg

Publication year - 2018

Publication title -

hematology/oncology and stem cell therapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.666

H-Index - 22

eISSN - 1658-3876

pISSN - 2589-0646

DOI - 10.1016/j.hemonc.2018.11.003

Subject(s) - medicine , surgery , romiplostim , transplantation , tranexamic acid , blood product , platelet transfusion , blood transfusion , packed red blood cells , population , thrombopoietin , platelet , blood loss , stem cell , environmental health , haematopoiesis , biology , genetics

Autologous stem cell transplant has been shown to prolong survival in multiple myeloma (MM). A common complication of the pre-transplant conditioning chemotherapy is severe multi-lineage cytopenias, resulting in significant transfusion requirements. Jehovah's Witnesses are members of a religious group that do not accept the transfusion of blood products. Many large transplant centers refuse to perform transplantation in Jehovah's Witnesses due to the complexity of treating cytopenic patients without blood product transfusions. However, some transplant centers that specialize in "bloodless" medicine and surgery have successfully transplanted in Jehovah's Witnesses without transfusion support.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research